SecBot SecBot
EFFECT ·Filed Nov 5, 2026

FULC

Fulcrum Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 20h ago SEC9999999995-26-003437
IPO/offering going effective
Actionable Insight • Neutral

The S-4 effectiveness signals an imminent shareholder vote or closing of a merger/acquisition. Monitor for the definitive proxy statement/prospectus and the terms of the transaction, including exchange ratio and any cash consideration.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$3.68
T+0 close · Nov 5, 2026 · via day close
Latest settled
0.00%
T+5 · $3.68
Vs SPY
−3.29%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $3.68entry
  2. T+1 · 11d ago +0.54%α +0.23% · $3.70
  3. T+5 · 5d ago 0.00%α −3.29% · $3.68
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics received SEC effectiveness for its S-4 registration statement (File No. 333-298705) on November 4, 2026. This allows the company to proceed with the business combination or exchange offer described in the S-4, typically a merger or acquisition involving stock consideration.

Key Facts

  • EFFECT notice filed November 5, 2026, with effectiveness date of November 4, 2026
  • Registration statement on Form S-4 (File No. 333-298705) declared effective
  • S-4 is used for business combinations, exchange offers, or reclassifications involving stock
  • Fulcrum Therapeutics is a pharmaceutical company with $279M market cap

Financial Impact

Effectiveness of S-4 enables a business combination; no financial terms disclosed in this filing

dilutioncapital structure

Risk Factors

  • S-4 effectiveness does not disclose the terms or valuation of the underlying transaction
  • Shareholder approval or regulatory conditions may still be pending
  • Potential dilution from stock issuance in the business combination

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-003437
Document: 9999999995-26-003437-index.html9999999995-26-003437
Document: 9999999995-26-003437.txt9999999995-26-003437

Track record

23 reports on FULC

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Viewing Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026